Advanced Malignant Solid Tumors
35
10
10
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
2.9%
1 terminated out of 35 trials
92.3%
+5.8% vs benchmark
0%
0 trials in Phase 3/4
58%
7 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (35)
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors
A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
A Study of TPD3310 in Patients With Advanced Malignant Tumors
Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
JSKN022 in Subjects With Advanced Malignant Solid Tumors
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor
Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors
A Study of GQ1010 in Subjects With Advanced Solid Tumors
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors
Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors